Literature DB >> 27647493

The 5-HT6 receptor antagonist idalopirdine potentiates the effects of donepezil on gamma oscillations in the frontal cortex of anesthetized and awake rats without affecting sleep-wake architecture.

Maria Amat-Foraster1, Steven C Leiser2, Kjartan F Herrik3, Nelly Richard4, Claus Agerskov5, Christoffer Bundgaard6, Jesper F Bastlund7, Inge E M de Jong8.   

Abstract

The 5-HT6 receptor is a promising target for cognitive disorders, in particular for Alzheimer's disease (AD). The high affinity and selective 5-HT6 receptor antagonist idalopirdine (Lu AE58054) is currently in development for mild-moderate AD as adjunct therapy to acetylcholinesterase inhibitors (AChEIs). We studied the effects of idalopirdine alone and in combination with the AChEI donepezil on cortical function using two in vivo electrophysiological methods. Neuronal network oscillations in the frontal cortex were measured during electrical stimulation of the brainstem nucleus pontis oralis (nPO) in the anesthetized rat and by an electroencephalogram (EEG) in the awake, freely moving rat. In conjunction with the EEG study, we investigated the effects of idalopirdine and donepezil on sleep-wake architecture using telemetric polysomnography. Idalopirdine (2 mg/kg i.v.) increased gamma power in the medial prefrontal cortex (mPFC) during nPO stimulation. Donepezil (0.3 and 1 mg/kg i.v.) also increased cortical gamma power and pretreatment with idalopirdine (2 mg/kg i.v.) potentiated and prolonged the effects of donepezil. Similarly, donepezil (1 and 3 mg/kg s.c.) dose-dependently increased frontal cortical gamma power in the freely moving rat and pretreatment with idalopirdine (10 mg/kg p.o.) augmented the effect of donepezil 1 mg/kg. Analysis of the sleep-wake architecture showed that donepezil (1 and 3 mg/kg s.c.) dose-dependently delayed sleep onset and decreased the time spent in both REM and non REM sleep stages. In contrast, idalopirdine (10 mg/kg p.o.) did not affect sleep-wake architecture nor the effects of donepezil. In summary, we show that idalopirdine potentiates the effects of donepezil on frontal cortical gamma oscillations, a pharmacodynamic biomarker associated with cognition, without modifying the effects of donepezil on sleep. The increased cortical excitability may contribute to the procognitive effects of idalopirdine in donepezil-treated AD patients. Copyright Â
© 2016 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  5-HT(6) receptor; Acetylcholinesterase inhibitor; Alzheimer's disease; Chemical compounds studied in this article: Donepezil (PubChem CID 3152); EEG; Idalopirdine; Idalopirdine (PubChem CID 21071390); sleep

Mesh:

Substances:

Year:  2016        PMID: 27647493     DOI: 10.1016/j.neuropharm.2016.09.017

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  6 in total

1.  The 5-HT and PLC Signaling Pathways Regulate the Secretion of IL-1β, TNF-α and BDNF from NG2 Cells.

Authors:  Tingting Yang; Yue Li; Hui Wang; Peng Shi; Liu Teng; Haibo Guo; Xiaohua Tu; Xinyu Yao
Journal:  Evid Based Complement Alternat Med       Date:  2022-05-13       Impact factor: 2.650

2.  Co-treatment with rivastigmine and idalopirdine reduces the propensity for falls in a rat model of falls in Parkinson's disease.

Authors:  Ajeesh Koshy Cherian; Aaron Kucinski; Ryan Wu; Inge E M de Jong; Martin Sarter
Journal:  Psychopharmacology (Berl)       Date:  2019-01-04       Impact factor: 4.530

3.  The CNS-Penetrant Soluble Guanylate Cyclase Stimulator CY6463 Reveals its Therapeutic Potential in Neurodegenerative Diseases.

Authors:  Susana S Correia; Rajesh R Iyengar; Peter Germano; Kim Tang; Sylvie G Bernier; Chad D Schwartzkopf; Jenny Tobin; Thomas W-H Lee; Guang Liu; Sarah Jacobson; Andrew Carvalho; Glen R Rennie; Joon Jung; Paul A Renhowe; Elisabeth Lonie; Christopher J Winrow; John R Hadcock; Juli E Jones; Mark G Currie
Journal:  Front Pharmacol       Date:  2021-05-24       Impact factor: 5.810

4.  The Serotonin Receptor 6 Antagonist Idalopirdine and Acetylcholinesterase Inhibitor Donepezil Have Synergistic Effects on Brain Activity-A Functional MRI Study in the Awake Rat.

Authors:  Craig F Ferris; Praveen Kulkarni; Jason R Yee; Mark Nedelman; Inge E M de Jong
Journal:  Front Pharmacol       Date:  2017-06-12       Impact factor: 5.810

5.  Stepwise occlusion of the carotid arteries of the rat: MRI assessment of the effect of donepezil and hypoperfusion-induced brain atrophy and white matter microstructural changes.

Authors:  Gabriella Nyitrai; Tamás Spisák; Zsófia Spisák; Dávid Gajári; Pálma Diószegi; Tamás Zsigmond Kincses; András Czurkó
Journal:  PLoS One       Date:  2018-05-31       Impact factor: 3.240

6.  Increasing Brain Gamma Activity Improves Episodic Memory and Restores Cholinergic Dysfunction in Alzheimer's Disease.

Authors:  Alberto Benussi; Valentina Cantoni; Mario Grassi; Lucie Brechet; Christoph M Michel; Abhishek Datta; Chris Thomas; Stefano Gazzina; Maria Sofia Cotelli; Marta Bianchi; Enrico Premi; Yasmine Gadola; Maria Cotelli; Marta Pengo; Federica Perrone; Maria Scolaro; Silvana Archetti; Eino Solje; Alessandro Padovani; Alvaro Pascual-Leone; Barbara Borroni
Journal:  Ann Neurol       Date:  2022-06-06       Impact factor: 11.274

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.